China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

LongBio Pharma, a prominent developer of innovative therapies for allergic and autoimmune diseases in China, has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange on June 5, 2026. The company issued shares at HK$96.06, which opened at HK$144.30, reflecting strong investor interest. With a market capitalization of HK$10.7 billion, this listing marks a significant achievement for LongBio Pharma and its major institutional investor, Qiming Venture Partners, which has been instrumental in the company's growth.

Founded in 2020, LongBio Pharma focuses on the in-house discovery and development of biopharmaceuticals targeting a range of conditions, including allergic rhinitis, asthma, and chronic urticaria. The company boasts a robust product pipeline, with its core product, LP-003, being a novel anti-IgE antibody that has shown superior efficacy compared to omalizumab in treating chronic spontaneous urticaria. Additionally, LP-005, another key product, is a bi-functional complement antibody-fusion protein that targets both C5 and C3b, positioning it competitively in the global market for complement inhibitors. The founding team, which includes experts like Dr. Sun Naichao and Dr. Liu Heng, brings extensive experience in drug development and commercialization, further enhancing the company's prospects.

Qiming Venture Partners, a leading venture capital firm established in 2006, has been a significant backer of LongBio Pharma, participating as the lead investor in its B2 financing round in 2024 and co-leading the C round in 2025. Prior to the IPO, Qiming held a 4.27 percent stake in the company. The firm's investment strategy focuses on addressing unmet clinical needs and supporting innovative medical solutions, which has proven resilient even during challenging market conditions. The successful IPO of LongBio Pharma is a testament to Qiming's ability to identify promising opportunities within the healthcare sector.

The IPO of LongBio Pharma comes at a time when the prevalence of allergic diseases is on the rise in China, creating a growing market for effective treatments. The listing not only facilitates LongBio Pharma's transition from laboratory research to commercialization but also signals a broader trend of increasing investor confidence in the Chinese biotech sector. As more companies pursue public offerings, the landscape for healthcare innovation in China is expected to evolve, potentially leading to accelerated development of new therapies and increased competition among biopharmaceutical firms.

In conclusion, the successful IPO of LongBio Pharma represents a significant milestone for the company and its investors, particularly Qiming Venture Partners. As the healthcare sector in China continues to expand, driven by rising demand for innovative treatments, LongBio Pharma is well-positioned to capitalize on market opportunities. The transaction underscores the potential for growth within the biotech industry and highlights the importance of strategic investments in addressing critical healthcare challenges.